EMA Authorised: Ximluci (ranibizumab) — STADA Arzneimittel AG

View source ↗

Summary

European Medicines Agency authorised Ximluci (ranibizumab) for indications including wet age-related macular degeneration, macular edema, and diabetic retinopat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Complications
• Diabetic Retinopathy
• Macular Edema
• Wet Macular Degeneration

Drugs mentioned

• Ximluci (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications. MAH: STADA Arzneimittel AG. Decision date: 26/03/2024